Navigation Links
New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
Date:4/23/2010

ons of Use

  • Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
  • Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones
  • Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
  • Welchol has not been studied in children younger than 10 years of age or in premenarchal girls

Contraindications

Welchol is contraindicated in individuals with bowel obstruction, those with serum triglyceride (TG) concentrations of >500 mg/dL, or with a history of hypertriglyceridemia-induced pancreatitis.

Warnings and Precautions

The effect of Welchol on cardiovascular morbidity and mortality has not been determined.  

Welchol can increase serum TG concentrations particularly when used in combination with sulfonylureas or insulin. Caution should be exercised when treating patients with TG levels >300 mg/dL.

Welchol may decrease the absorption of fat-soluble vitamins A, D, E and K. Patients on vitamin supplements should take their vitamins at least 4 hours prior to Welchol. Caution should be exercised when treating patients with a susceptibility to vitamin K or fat-soluble vitamin deficiencies.

Caution should also be exercised when treating patients with gastroparesis, gastrointestinal motility disorders, major gastrointestinal tract surgery, and when treating patients with dysphagia and swallowing disorders.

Welchol reduces gastrointestinal absorption of some drugs. Drugs with a known
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
2. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
3. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
4. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
5. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
6. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
7. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
10. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... SHENZHEN , Chine, 3 juillet 2015 ... séquençage à haut débit de l,ADN situé à ... la certification de  l,American College of Pathologists  (Collège ... BGI à Hong Kong ... nouvelle génération à recevoir la certification du CAP ...
(Date:7/2/2015)... and VANCOUVER , July 2, 2015 ... EPI) announced today that its common shares have been approved ... under the symbol "EPIX". ESSA will begin trading ... its listing on the TSX Venture Exchange under the symbol ... the common shares on the NASDAQ, each of the Company,s ...
(Date:7/2/2015)... July 2, 2015  New product launches are critical ... role in educating thought leaders about new products, Medical ... influence how well a new therapy performs at launch. ... research and consulting leader Best Practices, LLC, critical aspects ... focus on are early stage thought leader (TL) interaction, ...
Breaking Medicine Technology:BGI obtient la certification du Collège des pathologistes américains (CAP) 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 2ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 3ESSA Pharma Inc. to Commence Trading on the NASDAQ Capital Market 4Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2
... DALLAS, April 4, 2008 Data from five ... presented at the National Kidney,Foundation (NKF) 2008 Spring ... utilization studies involve PROCRIT(R) (Epoetin alfa)., The ... and,costs of PROCRIT (EPO) and darbepoetin alfa (DARB), ...
... Previously-Stated Guidance Remains Unchanged, PRINCETON, N.J., ... MEDX ) today issued the following statement ... that it was discontinuing its Phase 3 ... anti-CTLA-4,antibody (tremelimumab) compared to chemotherapy in patients ...
Cached Medicine Technology:Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 2Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 3Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 4Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 5Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings 6Medarex Announces Ipilimumab Program Continues to Move Forward 2Medarex Announces Ipilimumab Program Continues to Move Forward 3Medarex Announces Ipilimumab Program Continues to Move Forward 4Medarex Announces Ipilimumab Program Continues to Move Forward 5
(Date:7/3/2015)... ... July 03, 2015 , ... The Erie County Bar Association ... 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. of William Mattar Law ... of investigating these types of cases. , Each year, New York State residents ...
(Date:7/3/2015)... ... July 03, 2015 , ... " Selfie on a ... features the latest and coolest technology products available to consumers. Amanda Forstrom, a technology ... these selfie sticks are great for documenting memories. , Almost every smartphone has an ...
(Date:7/2/2015)... ... ... sweetFrog Enterprises, LLC. is pleased to announce the opening of its newest location in Dallas, ... The premium frozen yogurt chain was listed as #22 on the Inc. 500 list of ... at Bachman Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 ...
(Date:7/2/2015)... RI (PRWEB) , ... July 02, 2015 , ... Many ... safety in mind. That’s why Amica Insurance is sharing some tips to ... Commission (CPSC), approximately 230 people go to the emergency room daily with fireworks-related injuries ...
(Date:7/2/2015)... ... July 02, 2015 , ... Get ready to hit the ... Since the socks were first introduced, they have rapidly been gaining attention among ... four new, fun shades including: blue, lime, pink and red. , Utilizing ...
Breaking Medicine News(10 mins):Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2
... N.J., Nov. 2 comScore, Inc. (Nasdaq: ... world, and ImpactRx, a pharmaceutical insights company, today announced ... the only digital measurement solution that connects physicians, online ... This solution is carefully designed to comply with health ...
... to develop the disorder, study finds, , MONDAY, Nov. 2 ... by a strong urge to move the legs, is much ... U.S. study has found. , Researchers interviewed 190 people being ... those who were black, compared with 36 percent of those ...
... developing the brain disease, study finds , MONDAY, Nov. ... Alzheimer,s disease are at increased risk for high blood ... -- all of which may be associated with later ... a study by researchers in the Netherlands who compared ...
... PNAS provides a comprehensive comparative functional anatomy study in ... networks preserved across evolution. An international collaboration co-led ... York City examined patterns of connectivity to show that ... is actually divided into four distinct functional regions. ...
... walkability (degree of ease for walking) with local levels ... be good for walking, but have poor air quality. ... faculty member Julian Marshall and University of British Columbia ... highlight the need for urban design to consider both ...
... Richard L. ... ... Chief Executive Officer of Jackson Healthcare ®, Richard L. Jackson, will present at the ... Jackson will be part of a discussion panel addressing the tort reform debate and control ...
Cached Medicine News:Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 2Health News:comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution 3Health News:Restless Legs May Vary by Race and Gender 2Health News:High Blood Pressure Likely in Alzheimer's Offspring 2Health News:Researchers discover links between city walkability and air pollution exposure 2Health News:Researchers discover links between city walkability and air pollution exposure 3Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 2Health News:CEO of Jackson Healthcare to Speak at Physicians' Council for Responsible Reform Upcoming Strategy Meeting 3
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only....
... ideally suited for high volume stone centers. This ... and an advanced urological table. With the Dornier ... provides successful treatments for a full range of ... URS and PCN procedures are easy. One of ...
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: